Nanoscope Therapeutics Press Releases
-
Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa
March 30, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Appoints Industry Veteran Vicente Anido Jr., Ph.D., as a Strategic Advisor
March 20, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces World Health Organization Selection of “Sonpiretigene Isteparvovec” as International Nonproprietary Name for MCO-010
February 28, 2023 by Nanoscope Therapeutics
-
Nanoscope Therapeutics CEO Sulagna Bhattacharya Joins BIO Health Section Governing Board
February 13, 2023 by Nanoscope Therapeutics
Nanoscope Therapeutics In the News
- The Future 50 in Dallas-Fort Worth 2023: Meet the Game-Changing Disruptors Driving Innovation and Impace
- Modern Retina: Nanoscope Therapeutics announces WHO selection of ‘sonpiretigene isteparvovec’ as international nonproprietary name for MCO-010
- CGT Live: 10 Cell and Gene Therapies to Watch in 2023
- Modern Retina: FDA grants fast track designation to Nanoscope Therapeutics for MCO-010 for the treatment of retinitis pigmentosa
- Ocular Surgery News: Retinitis Pigmentosa Treatment Receives Fast Track Designation
Upcoming Nanoscope Therapeutics Events
- Apr 23-27 2023 | ARVO Annual Meeting – New Orleans
- May 16-20, 2023 | ASGCT Annual Meeting | Los Angeles
- May 23-25, 2023 | World Orphan Drug Congress | Washington DC
- June 5-8, 2023 | BIO International Convention – Boston
- June 10, 2023 | Clinical Trials at the Summit | Park City, UT
- June 12-13, 2023 | 9th Annual Brain Initiative Meeting
- July 27, 2023 | OIS Retina Innovation Summit | Seattle
- July 28- Aug 1, 2023 | American Society of Retina Specialists Annual Meeting | Seattle
- Oct 5-8, 2023 | 23rd Euretina Congress | Amsterdam
- Oct 11-14, 2023 | The Retina Society Annual Scientific Meeting | New York